Biomarin Debt Ratio from 2010 to 2025

BMRN Stock

USD 69.07 0.26 0.38%

Biomarin Pharmaceutical Debt Ratio yearly trend continues to be very stable with very little volatility. Debt Ratio is likely to drop to 0.08. During the period from 2010 to 2025, Biomarin Pharmaceutical Debt Ratio quarterly data regression pattern had sample variance of 0.01 and median of 0.18. View All Fundamentals

Debt Ratio

First Reported

2010-12-31

Previous Quarter

0.08515426

Current Value

0.0809

Quarterly Volatility

0.07513362

Credit Downgrade

Yuan Drop

Covid

Check Biomarin Pharmaceutical financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Biomarin Pharmaceutical's main balance sheet or income statement drivers, such as Depreciation And Amortization of 126 M, Selling General Administrative of 1.1 B or Total Revenue of 3 B, as well as many indicators such as Price To Sales Ratio of 4.16, Dividend Yield of 0.0 or PTB Ratio of 3.91. Biomarin financial statements analysis is a perfect complement when working with Biomarin Pharmaceutical Valuation or Volatility modules.

Check out the analysis of Biomarin Pharmaceutical Correlation against competitors.

To learn how to invest in Biomarin Stock, please use our How to Invest in Biomarin Pharmaceutical guide.

Latest Biomarin Pharmaceutical's Debt Ratio Growth Pattern

Below is the plot of the Debt Ratio of Biomarin Pharmaceutical over the last few years. It is Biomarin Pharmaceutical's Debt Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Biomarin Pharmaceutical's overall financial position and show how it may be relating to other accounts over time.

Debt Ratio

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Debt Ratio

Timeline

Biomarin Debt Ratio Regression Statistics

	Arithmetic Mean	0.18
	Geometric Mean	0.14
	Coefficient Of Variation	41.85
	Mean Deviation	0.05
	Median	0.18
	Standard Deviation	0.08
	Sample Variance	0.01
	Range	0.2883
	R-Value	(0.33)
	Mean Square Error	0.01
	R-Squared	0.11
	Significance	0.22
	Slope	(0.01)
	Total Sum of Squares	0.08

Biomarin Debt Ratio History

	2025	0.0809
	2024	0.0852
	2023	0.16
	2018	0.19
	2017	0.25
	2016	0.17
	2015	0.18

Other Fundumenentals of Biomarin Pharmaceutical

Cash Flow To Debt Ratio

Biomarin Pharmaceutical Debt Ratio component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Total Liab	Total Current Assets	Intangible Assets	Short Term Investments	Short Term Debt	Common Stock	Long Term Debt	Property Plant Equipment	Current Deferred Revenue	Good Will	Net Tangible Assets	Long Term Debt Total	Capital Surpluse	Long Term Investments	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.99	0.03	-0.11	0.4	0.95	0.78	0.97	0.41	0.46	0.23	0.77	0.64	0.98	0.43	0.79	0.97	0.84	0.9	0.73	-0.48	0.8	0.67	0.74
Total Stockholder Equity	0.99		-0.09	0.01	0.31	0.97	0.68	0.97	0.31	0.37	0.23	0.71	0.56	0.97	0.39	0.73	0.99	0.82	0.85	0.7	-0.46	0.85	0.73	0.82
Net Debt	0.03	-0.09		-0.64	0.38	-0.16	0.53	-0.1	0.55	0.65	-0.48	0.25	0.42	0.03	-0.03	0.38	-0.13	0.06	0.25	0.19	-0.15	-0.22	-0.38	-0.47
Retained Earnings	-0.11	0.01	-0.64		-0.84	0.09	-0.57	-0.06	-0.76	-0.65	0.0	-0.47	-0.44	-0.22	-0.38	-0.5	0.1	-0.03	-0.39	-0.26	0.53	0.44	0.47	0.45
Accounts Payable	0.4	0.31	0.38	-0.84		0.26	0.66	0.35	0.79	0.5	0.29	0.63	0.33	0.51	0.5	0.71	0.21	0.2	0.61	0.52	-0.54	-0.12	-0.21	-0.11
Net Receivables	0.95	0.97	-0.16	0.09	0.26		0.6	0.96	0.18	0.29	0.26	0.64	0.41	0.93	0.3	0.64	0.97	0.75	0.79	0.62	-0.4	0.86	0.72	0.85
Total Liab	0.78	0.68	0.53	-0.57	0.66	0.6		0.71	0.68	0.71	0.11	0.89	0.82	0.78	0.48	0.86	0.63	0.76	0.89	0.68	-0.41	0.44	0.28	0.18
Total Current Assets	0.97	0.97	-0.1	-0.06	0.35	0.96	0.71		0.27	0.45	0.31	0.73	0.58	0.96	0.42	0.69	0.96	0.82	0.84	0.62	-0.44	0.8	0.7	0.78
Intangible Assets	0.41	0.31	0.55	-0.76	0.79	0.18	0.68	0.27		0.58	0.08	0.61	0.55	0.48	0.41	0.78	0.2	0.29	0.58	0.57	-0.51	-0.1	-0.11	-0.14
Short Term Investments	0.46	0.37	0.65	-0.65	0.5	0.29	0.71	0.45	0.58		-0.21	0.53	0.66	0.49	0.24	0.61	0.33	0.43	0.59	0.31	-0.51	0.08	0.09	-0.01
Short Term Debt	0.23	0.23	-0.48	0.0	0.29	0.26	0.11	0.31	0.08	-0.21		0.25	-0.03	0.24	0.45	0.05	0.17	0.14	0.1	0.2	0.11	0.07	0.07	0.28
Common Stock	0.77	0.71	0.25	-0.47	0.63	0.64	0.89	0.73	0.61	0.53	0.25		0.74	0.79	0.36	0.81	0.64	0.76	0.87	0.67	-0.43	0.47	0.43	0.23
Long Term Debt	0.64	0.56	0.42	-0.44	0.33	0.41	0.82	0.58	0.55	0.66	-0.03	0.74		0.62	0.4	0.63	0.53	0.74	0.69	0.37	-0.26	0.36	0.36	0.12
Property Plant Equipment	0.98	0.97	0.03	-0.22	0.51	0.93	0.78	0.96	0.48	0.49	0.24	0.79	0.62		0.46	0.82	0.93	0.78	0.91	0.7	-0.56	0.71	0.6	0.7
Current Deferred Revenue	0.43	0.39	-0.03	-0.38	0.5	0.3	0.48	0.42	0.41	0.24	0.45	0.36	0.4	0.46		0.52	0.38	0.49	0.54	0.52	-0.38	0.15	0.1	0.15
Good Will	0.79	0.73	0.38	-0.5	0.71	0.64	0.86	0.69	0.78	0.61	0.05	0.81	0.63	0.82	0.52		0.67	0.72	0.94	0.8	-0.59	0.46	0.4	0.26
Net Tangible Assets	0.97	0.99	-0.13	0.1	0.21	0.97	0.63	0.96	0.2	0.33	0.17	0.64	0.53	0.93	0.38	0.67		0.82	0.82	0.65	-0.41	0.89	0.78	0.84
Long Term Debt Total	0.84	0.82	0.06	-0.03	0.2	0.75	0.76	0.82	0.29	0.43	0.14	0.76	0.74	0.78	0.49	0.72	0.82		0.85	0.62	-0.25	0.8	0.78	0.48
Capital Surpluse	0.9	0.85	0.25	-0.39	0.61	0.79	0.89	0.84	0.58	0.59	0.1	0.87	0.69	0.91	0.54	0.94	0.82	0.85		0.77	-0.56	0.63	0.54	0.41
Long Term Investments	0.73	0.7	0.19	-0.26	0.52	0.62	0.68	0.62	0.57	0.31	0.2	0.67	0.37	0.7	0.52	0.8	0.65	0.62	0.77		-0.58	0.53	0.34	0.4
Short Long Term Debt	-0.48	-0.46	-0.15	0.53	-0.54	-0.4	-0.41	-0.44	-0.51	-0.51	0.11	-0.43	-0.26	-0.56	-0.38	-0.59	-0.41	-0.25	-0.56	-0.58		-0.1	-0.08	-0.23
Net Invested Capital	0.8	0.85	-0.22	0.44	-0.12	0.86	0.44	0.8	-0.1	0.08	0.07	0.47	0.36	0.71	0.15	0.46	0.89	0.8	0.63	0.53	-0.1		0.88	0.8
Net Working Capital	0.67	0.73	-0.38	0.47	-0.21	0.72	0.28	0.7	-0.11	0.09	0.07	0.43	0.36	0.6	0.1	0.4	0.78	0.78	0.54	0.34	-0.08	0.88		0.69
Capital Stock	0.74	0.82	-0.47	0.45	-0.11	0.85	0.18	0.78	-0.14	-0.01	0.28	0.23	0.12	0.7	0.15	0.26	0.84	0.48	0.41	0.4	-0.23	0.8	0.69

Click cells to compare fundamentals

About Biomarin Pharmaceutical Financial Statements

Biomarin Pharmaceutical investors utilize fundamental indicators, such as Debt Ratio, to predict how Biomarin Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.

	Last Reported	Projected for Next Year
Debt Ratio	0.09	0.08
Cash Flow To Debt Ratio	0.96	1.01

When determining whether Biomarin Pharmaceutical offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Biomarin Pharmaceutical's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biomarin Pharmaceutical Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biomarin Pharmaceutical Stock:

How To Invest In Biomarin

Details

Is Biomarin Stock a good investment?

Details

What is Biomarin Pharmaceutical's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out the analysis of Biomarin Pharmaceutical Correlation against competitors.

To learn how to invest in Biomarin Stock, please use our How to Invest in Biomarin Pharmaceutical guide.

You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biomarin Pharmaceutical. If investors know Biomarin will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biomarin Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

6.449

Earnings Share

2.13

Revenue Per Share

15.018

Quarterly Revenue Growth

0.156

Return On Assets

0.0515

The market value of Biomarin Pharmaceutical is measured differently than its book value, which is the value of Biomarin that is recorded on the company's balance sheet. Investors also form their own opinion of Biomarin Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Biomarin Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biomarin Pharmaceutical's market value can be influenced by many factors that don't directly affect Biomarin Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Biomarin Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biomarin Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biomarin Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Biomarin Debt Ratio from 2010 to 2025

Latest Biomarin Pharmaceutical's Debt Ratio Growth Pattern

Biomarin Debt Ratio Regression Statistics

Biomarin Debt Ratio History

Other Fundumenentals of Biomarin Pharmaceutical

Biomarin Pharmaceutical Debt Ratio component correlations

About Biomarin Pharmaceutical Financial Statements

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY